Coherus Oncology reports 89% confirmed response rate for tagmokitug combination in first-line esophageal cancer trial

Bitget2026/10/29 12:17

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Coherus Oncology announced interim tagmokitug trial results on October 28, 2026, supporting expanded enrollment in first- and second-line esophageal cancer cohorts.
First-line treatment with toripalimab and chemotherapy showed tumor responses regardless of PD-L1 status; second-line treatment showed durable clinical benefit.
Safety findings showed manageable tolerability with no new safety signals, supporting continued development.
Further evaluation will assess response durability, progression-free survival and biomarkers as the data mature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-119912), on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Coherus Oncology reports 89% confirmed response rate for tagmokitug combination in first-line esophageal cancer trial

You may also like

Crypto prices